Protection against glucose-induced neuronal death by NAAG and GCP II inhibition is regulated by mGluR3

Alison Berent-Spillson, Amanda M. Robinson, David Golovoy, Barbara Slusher, Camilo Rojas, James W. Russell

Research output: Contribution to journalArticle

Abstract

Glutamate carboxypeptidase II (GCP II) inhibition has previously been shown to be protective against long-term neuropathy in diabetic animals. In the current study, we have determined that the GCP II inhibitor 2-(phosphonomethyl) pentanedioic acid (2-PMPA) is protective against glucose-induced programmed cell death (PCD) and neurite degeneration in dorsal root ganglion (DRG) neurons in a cell culture model of diabetic neuropathy. In this model, inhibition of caspase activation is mediated through the group II metabotropic glutamate receptor, mGluR3. 2-PMPA neuroprotection is completely reversed by the mGluR3 antagonist (S)-α-ethylglutamic acid (EGLU). In contrast, group I and III mGluR inhibitors have no effect on 2-PMPA neuroprotection. Furthermore, we show that two mGluR3 agonists, the direct agonist (2R,4R)-4-aminopyrrolidine-2, 4-dicarboxylate (APDC) and N-acetyl-aspartyl-glutamate (NAAG) provide protection to neurons exposed to high glucose conditions, consistent with the concept that 2-PMPA neuroprotection is mediated by increased NAAG activity. Inhibition of GCP II or mGluR3 may represent a novel mechanism to treat neuronal degeneration under high-glucose conditions.

Original languageEnglish (US)
Pages (from-to)90-99
Number of pages10
JournalJournal of Neurochemistry
Volume89
Issue number1
StatePublished - Apr 2004
Externally publishedYes

Fingerprint

Glutamate Carboxypeptidase II
Glucose
Diabetic Neuropathies
Neurons
Metabotropic Glutamate Receptors
Spinal Ganglia
Neurites
Cell death
Caspases
Cell culture
Animals
Cell Death
Cell Culture Techniques
Chemical activation
Acids
2-(phosphonomethyl)pentanedioic acid
Neuroprotection
metabotropic glutamate receptor 3
N-acetyl-1-aspartylglutamic acid

Keywords

  • Apoptosis
  • Diabetes
  • Dorsal root ganglia
  • Glutamate carboxypeptidase II
  • Metabotropic glutamate receptor
  • N-acetyl-aspartyl-glutamate

ASJC Scopus subject areas

  • Biochemistry
  • Cellular and Molecular Neuroscience

Cite this

Protection against glucose-induced neuronal death by NAAG and GCP II inhibition is regulated by mGluR3. / Berent-Spillson, Alison; Robinson, Amanda M.; Golovoy, David; Slusher, Barbara; Rojas, Camilo; Russell, James W.

In: Journal of Neurochemistry, Vol. 89, No. 1, 04.2004, p. 90-99.

Research output: Contribution to journalArticle

Berent-Spillson, Alison ; Robinson, Amanda M. ; Golovoy, David ; Slusher, Barbara ; Rojas, Camilo ; Russell, James W. / Protection against glucose-induced neuronal death by NAAG and GCP II inhibition is regulated by mGluR3. In: Journal of Neurochemistry. 2004 ; Vol. 89, No. 1. pp. 90-99.
@article{750cc1bf554b44e5b629f0b9895ce36d,
title = "Protection against glucose-induced neuronal death by NAAG and GCP II inhibition is regulated by mGluR3",
abstract = "Glutamate carboxypeptidase II (GCP II) inhibition has previously been shown to be protective against long-term neuropathy in diabetic animals. In the current study, we have determined that the GCP II inhibitor 2-(phosphonomethyl) pentanedioic acid (2-PMPA) is protective against glucose-induced programmed cell death (PCD) and neurite degeneration in dorsal root ganglion (DRG) neurons in a cell culture model of diabetic neuropathy. In this model, inhibition of caspase activation is mediated through the group II metabotropic glutamate receptor, mGluR3. 2-PMPA neuroprotection is completely reversed by the mGluR3 antagonist (S)-α-ethylglutamic acid (EGLU). In contrast, group I and III mGluR inhibitors have no effect on 2-PMPA neuroprotection. Furthermore, we show that two mGluR3 agonists, the direct agonist (2R,4R)-4-aminopyrrolidine-2, 4-dicarboxylate (APDC) and N-acetyl-aspartyl-glutamate (NAAG) provide protection to neurons exposed to high glucose conditions, consistent with the concept that 2-PMPA neuroprotection is mediated by increased NAAG activity. Inhibition of GCP II or mGluR3 may represent a novel mechanism to treat neuronal degeneration under high-glucose conditions.",
keywords = "Apoptosis, Diabetes, Dorsal root ganglia, Glutamate carboxypeptidase II, Metabotropic glutamate receptor, N-acetyl-aspartyl-glutamate",
author = "Alison Berent-Spillson and Robinson, {Amanda M.} and David Golovoy and Barbara Slusher and Camilo Rojas and Russell, {James W.}",
year = "2004",
month = "4",
language = "English (US)",
volume = "89",
pages = "90--99",
journal = "Journal of Neurochemistry",
issn = "0022-3042",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Protection against glucose-induced neuronal death by NAAG and GCP II inhibition is regulated by mGluR3

AU - Berent-Spillson, Alison

AU - Robinson, Amanda M.

AU - Golovoy, David

AU - Slusher, Barbara

AU - Rojas, Camilo

AU - Russell, James W.

PY - 2004/4

Y1 - 2004/4

N2 - Glutamate carboxypeptidase II (GCP II) inhibition has previously been shown to be protective against long-term neuropathy in diabetic animals. In the current study, we have determined that the GCP II inhibitor 2-(phosphonomethyl) pentanedioic acid (2-PMPA) is protective against glucose-induced programmed cell death (PCD) and neurite degeneration in dorsal root ganglion (DRG) neurons in a cell culture model of diabetic neuropathy. In this model, inhibition of caspase activation is mediated through the group II metabotropic glutamate receptor, mGluR3. 2-PMPA neuroprotection is completely reversed by the mGluR3 antagonist (S)-α-ethylglutamic acid (EGLU). In contrast, group I and III mGluR inhibitors have no effect on 2-PMPA neuroprotection. Furthermore, we show that two mGluR3 agonists, the direct agonist (2R,4R)-4-aminopyrrolidine-2, 4-dicarboxylate (APDC) and N-acetyl-aspartyl-glutamate (NAAG) provide protection to neurons exposed to high glucose conditions, consistent with the concept that 2-PMPA neuroprotection is mediated by increased NAAG activity. Inhibition of GCP II or mGluR3 may represent a novel mechanism to treat neuronal degeneration under high-glucose conditions.

AB - Glutamate carboxypeptidase II (GCP II) inhibition has previously been shown to be protective against long-term neuropathy in diabetic animals. In the current study, we have determined that the GCP II inhibitor 2-(phosphonomethyl) pentanedioic acid (2-PMPA) is protective against glucose-induced programmed cell death (PCD) and neurite degeneration in dorsal root ganglion (DRG) neurons in a cell culture model of diabetic neuropathy. In this model, inhibition of caspase activation is mediated through the group II metabotropic glutamate receptor, mGluR3. 2-PMPA neuroprotection is completely reversed by the mGluR3 antagonist (S)-α-ethylglutamic acid (EGLU). In contrast, group I and III mGluR inhibitors have no effect on 2-PMPA neuroprotection. Furthermore, we show that two mGluR3 agonists, the direct agonist (2R,4R)-4-aminopyrrolidine-2, 4-dicarboxylate (APDC) and N-acetyl-aspartyl-glutamate (NAAG) provide protection to neurons exposed to high glucose conditions, consistent with the concept that 2-PMPA neuroprotection is mediated by increased NAAG activity. Inhibition of GCP II or mGluR3 may represent a novel mechanism to treat neuronal degeneration under high-glucose conditions.

KW - Apoptosis

KW - Diabetes

KW - Dorsal root ganglia

KW - Glutamate carboxypeptidase II

KW - Metabotropic glutamate receptor

KW - N-acetyl-aspartyl-glutamate

UR - http://www.scopus.com/inward/record.url?scp=1842562427&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842562427&partnerID=8YFLogxK

M3 - Article

VL - 89

SP - 90

EP - 99

JO - Journal of Neurochemistry

JF - Journal of Neurochemistry

SN - 0022-3042

IS - 1

ER -